Alkermes Highlights Strong Phase 2 Data for Alixorexton at SLEEP 2026
DUBLIN, June 17, 2026 Alkermes plc announced detailed positive results from the Phase 2 Vibrance-2 clinical trial evaluating alixorexton,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
DUBLIN, June 17, 2026 Alkermes plc announced detailed positive results from the Phase 2 Vibrance-2 clinical trial evaluating alixorexton,...
